Sunday, February 01, 2015 12:47:21 AM
A single use of a drug prophylatically may be fairly innocuous, but repeated uses is another question entirely. This is particularly so for nanoviricides in which continuous use would effectively inactive a number of very important cell surface receptors important to immune functions.
Most antibiotics are approved for single use for an acute infection. Continuous or oft repeated use would raise very serious safety issues.
Note also that some vaccines are therapeutic: i.e.: effective even when given post infection (of course the infection can't be too advanced) Smallpox vaccine is totally curative even when given several days after infection.
The key point is that, while you can use drugs prophylatically in a limited number of cases, this cannot be done for an entire population as vaccines can. And it cannot be used to protect HCWs as vaccines can, because for drugs it would require that they take the drug continuously through an entire epidemic.
For as long as you take a nanoviricide the cell surface receptors that the nanoviricide imitates are going to be effectively rendered useless as the ligands that activate them are all trapped by the nanoviricides. Important parts of the immune system would be rendered dysfunctional - a particularly dangerous state for HCWs and others with increased exposure.
Population vaccines are simple, highly efficient and very low cost per vaccination. For epidemics local centers are set up and everyone in an area gets their vaccinations within a short time span. And one low cost HCW can vaccinate many hundreds of people per day.
"could possibly"! Get real! Even a weakly effective vaccine would save a very large number of lives. That's especially true when you take herd immunity into account. And it would be true for a vaccine for a highly lethal disease like Ebola even if a vaccine had considerably greater than usual safety issues. IMHO your skepticism is considerably overdone.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM